
## Immunothrombosis & COVID-19


This week we highlight SAIS/Immunopaedia COVID-19 Webinar featuring talks by haematopathologists Dr Susan Louw and A/Prof Jessica Olpie on immunothrombosis & COVID-19. Immunothrombosis is the direct interaction of activated leukocytes with platelets and coagulation function, this interaction usually involves dysregulation of neutrophil extracellular trap formation.



Dr Susan Louw began her talk titled "Immunothrombosis: lessons from other conditions" with a brief background on Thrombosis and how physiological process if left unchecked can lead to pathology. She

discussed how cross-talk between the immune system (macrophages, complement proteins, neutrophils) and coagulation cascade (platelets and tissue factors) can cause to immunothrombosis. She then gave an in-depth yet brief


overview of how coagulation proteins engage with the complement cascade (see image below) and the role of innate cells (macrophages and neutrophils) and cytokines in



immunothrombosis. Further, she then highlighted that platelets, well known for their role in blood-clotting, have immunomodulatory properties. Dr Louw concluded her talk describing clinical conditions associated with immunothrombosis (see below).


Clinical condition	Congulation dyntunction	Complement dysfunction
Sepsis	Potent activator of coagulation via tasse factor with endothelial dyskunction	Activation of multiple complement pathways
Trauma Induced coagelepathy	Potent activator of ocagalation, hyperflorinolysis and DC	Increased CBa and C6d on surface of platelets
Systemic lupus erythematosus (SUE)	Complement promotes platelot activation and thrumitoxia; APLAs activate samplement and coagulation cascade	Complement activation by nuclear autoantibodies; Deficiencies and mutations in other classical partway proteins; Reduced repression of complement inhibitars
Antiphospholipid Syndrome	Classprepaletes TT on neutrophils which then activates cospulation with inflammation, trophobiost injury and foetal death	APLAs activate complement on traphoblasts leading to C5a generation
Auto- and alloimmune haemolytic anaemia	Complement-modiated RBC hysis causes activation of opagelistion ela - Expension of phospeticlyherine - Melese of tissue factor beering microparticles - Endothelial cell injury - Altered vasodynamics - Release of reactive copper species	Activation of the classical complement pathway by IgM antibody-bound aggintwated INEs bind CL: bitmescalar hermicipal of CB-coated erythrocytes; Activation of complement by circulating free have:

Clinical condition	Congulation dystunction	Complement dysfunction	<b>1</b>
Paresysmal methonal haamoglobinaria	Platelet activation: Assence of OPHinked a An receptor with impaired flationdpris: Endothelial dystanction from free hearmoglobin and with contor depletion; MAC and CSa generation pormote thrembosic HB premote theoretic generation and Inhibit ADA/17513	Complement mediated harmolysis by sanegulated production of MAC on cell surfaces; CSa upregulates US, US, TMP a	
Atypical haamslytic umamic synchrona	Endothelial cell damage and disruption of microvaculations with thrombells; Platelation are activated by IAAC on CSa Unopposed complement-medicited destruction of platelation (due to lack of Factor ill and other menintance regulation).	Dynapplation of alternate CP and C8 convertage activity due to ious of inhibitory complement	
Hereditary angloedema	Unregulated activation of prekalikosin- katikosin-HMMMK bradykinin-duar to CLHMH deficiency or dynfunction	Deficiency/dysfunction of C1-inhibitor results in loss of neutralicing C1s, C1r and MAGPs thus dysregulating OP and UP	
by Hill-associated chronic inflammation -	elial injury by HW Hostif, / demage by opport - local activation of computation (seliated, al- release of WWF: evenwhering ACAMTS-13 - intercomplexitie drawnikosis enction must be delineated	evated D-dimens)	



Jessica Opie's talk focused on "Thrombosis in COVID-19". A/Prof Opie gave an overview of homeostatic properties [coagulation factors (clot

formation), coagulation inhibitors (clot controlling) and fibrinolysis (clot-dissolving)] associated with blood vessel injury. She then provided evidence which demonstrated that severe COVID-19 pathology is associated with dysregulation of tissue repair and blood vessel formation of the lung endothelial membrane. She also discussed how cytokine storm and dysregulation of the complement pathway contributes to excessive NETosis and is associated with severe COVID-19 pathologies (such as hypercoagulability, endotheliopathy, macrothromboisis and microthromobisis). She ended her talk describing how targeting either NETosis (using NET inhibitors) and the complement cascade could be potential therapies for severe COVID-19.



Summary by Cheleka Mpande